Vitiligo – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:07:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Vitiligo – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo https://clinicaltrials.eu/trial/phase-iib-randomized-study-of-gia632-vs-placebo-to-assess-efficacy-and-safety-in-adults-with-nonsegmental-vitiligo/ Wed, 17 Jun 2026 04:03:04 +0000 https://clinicaltrials.eu/trial/phase-iib-randomized-study-of-gia632-vs-placebo-to-assess-efficacy-and-safety-in-adults-with-nonsegmental-vitiligo/ Non‑segmental vitiligo is a skin condition in which the immune system gradually removes pigment from large areas of the skin, often affecting the face and visible parts of the body. The study is testing a new medication called GIA632, which is given as a small injection under the skin, and comparing it with a harmless substance known as placebo to see if it can help restore color to the affected areas.

The main goal of the trial is to find the dose of GIA632 that works best for increasing skin color in people with this type of vitiligo. Participants will receive a series of injections over several months, with regular check‑ins to monitor any changes in the appearance of the skin and to watch for possible side effects. The study also uses a simple scoring system called the facial Vitiligo Area Scoring Index to measure how much the facial skin has repigmented, helping researchers understand whether the treatment is effective and safe.

]]> Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo https://clinicaltrials.eu/trial/efficacy-and-safety-of-ly4005130-compared-with-placebo-in-adults-with-non-segmental-vitiligo/ Sun, 31 May 2026 04:02:47 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-of-ly4005130-compared-with-placebo-in-adults-with-non-segmental-vitiligo/ Non-Segmental Vitiligo is a skin disorder in which patches of skin lose pigment, creating white spots that can appear on the face and other areas. The study evaluates an intravenous solution called LY4005130 as a possible new treatment for this condition.

The purpose of the study is to compare the effectiveness of LY4005130 with placebo in adults with the disorder. Participants are randomly assigned to receive either the study drug or a dummy treatment, given by infusion over several visits during a 24‑week period. The main outcome measured is the proportion of participants who reach a 75 % improvement on the facial Vitiligo Area Scoring Index (F-VASI), a score that estimates how much of the face is repigmented. Regular check‑ins monitor safety and any changes in skin color.

]]> Study on Ritlecitinib for Adults and Adolescents with Nonsegmental Vitiligo https://clinicaltrials.eu/trial/study-on-ritlecitinib-for-adults-and-adolescents-with-nonsegmental-vitiligo/ Mon, 04 May 2026 07:50:20 +0000 https://clinicaltrials.eu/trial/study-on-ritlecitinib-for-adults-and-adolescents-with-nonsegmental-vitiligo/ This clinical trial is focused on studying nonsegmental vitiligo, a condition where patches of skin lose their color. The study is testing a treatment called Ritlecitinib tosilate, which is taken as a capsule. Participants will be randomly assigned to receive either the treatment or a placebo, which looks like the treatment but does not contain the active medicine. The purpose of the study is to evaluate how effective, safe, and tolerable the treatment is for people with nonsegmental vitiligo.

The study will last for 52 weeks, during which participants will take the medication daily. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. These check-ups will help researchers understand how well the treatment works and if there are any side effects. The study aims to see if the treatment can improve the skin condition by at least 75% over the course of the study.

Participants in the study will include adults and adolescents who have been diagnosed with nonsegmental vitiligo for at least three months. The study will help gather important information about the potential benefits and risks of using Ritlecitinib tosilate for treating this condition. This information could lead to new treatment options for people living with nonsegmental vitiligo.

]]> A study to evaluate the effectiveness of oxygen and narrow-band UVB phototherapy for treating patients with diffuse vitiligo https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-oxygen-and-narrow-band-uvb-phototherapy-for-treating-patients-with-diffuse-vitiligo/ Wed, 29 Apr 2026 15:09:38 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-oxygen-and-narrow-band-uvb-phototherapy-for-treating-patients-with-diffuse-vitiligo/ This study focuses on the treatment of vitiligo, a condition where the skin loses its natural color due to the loss of pigment-producing cells. The research aims to evaluate how a combination of two different treatments works together to manage this condition. The treatments being tested are hyperbaric oxygen therapy, which involves breathing oxygen in a pressurized chamber, and narrowband ultraviolet B therapy, a type of light therapy used on the skin.

Participants in this study will undergo a period of treatment lasting 24 weeks. During this time, the combination of pressurized oxygen and light therapy will be applied to assess how well they help restore skin color. The process involves regular visits to monitor the skin’s appearance and any changes in the affected areas over the course of the intervention.

]]> A study comparing how ritlecitinib capsules work when sprinkled on food versus swallowed whole and with or without food in healthy adults https://clinicaltrials.eu/trial/a-study-comparing-how-ritlecitinib-capsules-work-when-sprinkled-on-food-versus-swallowed-whole-and-with-or-without-food-in-healthy-adults/ Wed, 29 Apr 2026 15:08:27 +0000 https://clinicaltrials.eu/trial/a-study-comparing-how-ritlecitinib-capsules-work-when-sprinkled-on-food-versus-swallowed-whole-and-with-or-without-food-in-healthy-adults/ This study involves Ritlecitinib, a medicine being tested for several conditions including Alopecia Areata, which is a condition that causes hair loss in patches, Rheumatoid Arthritis, which is a disease where the body’s immune system attacks the joints causing pain and swelling, Vitiligo, which is a condition that causes loss of skin color in patches, Ulcerative Colitis, which is a disease that causes inflammation and sores in the lining of the large intestine, and Crohn’s Disease, which is a condition that causes inflammation of the digestive tract. The medicine comes in the form of a hard capsule that can be taken by mouth. The study will look at how the body absorbs the medicine when the capsule contents are sprinkled on different foods compared to when the capsule is swallowed whole.

The purpose of this study is to measure how much of the medicine gets into the bloodstream when the capsule is opened and sprinkled on applesauce, strawberry jam, or yoghurt compared to swallowing the capsule whole without food, and also to see how eating food affects the amount of medicine that gets into the bloodstream when the capsule is swallowed whole. This information is important for understanding different ways the medicine can be taken, especially for people who may have difficulty swallowing capsules. The study will involve healthy adult participants who will receive a 30 mg dose of the medicine in different ways during the study.

Participants will take part in a study where they will receive the medicine in different forms on different occasions, allowing researchers to compare how the body processes the medicine under various conditions. Blood samples will be collected to measure the amount of medicine in the bloodstream over time. The study will monitor participants for any unwanted effects that may occur during the treatment period.

]]> Testing delgocitinib cream for patients with vitiligo on the face https://clinicaltrials.eu/trial/testing-delgocitinib-cream-for-patients-with-vitiligo-on-the-face/ Wed, 29 Apr 2026 15:08:22 +0000 https://clinicaltrials.eu/trial/testing-delgocitinib-cream-for-patients-with-vitiligo-on-the-face/ This study is looking at a condition called vitiligo, which is a skin disorder where patches of skin lose their natural color and become white. The study focuses specifically on vitiligo that affects the face. The treatment being tested is a cream called Anzupgo, which contains an active ingredient named delgocitinib. This cream is applied directly to the skin in the areas affected by vitiligo.

The purpose of this study is to find out whether delgocitinib cream could be a helpful treatment for people who have non-segmental vitiligo on their face. Non-segmental vitiligo means the white patches appear on both sides of the body rather than just one side. During the study, participants will apply the cream to their facial vitiligo patches for a period of 24 weeks. The study will measure changes in the amount and appearance of the white patches on the face and other parts of the body at different time points, including after 4 weeks, 12 weeks, and 24 weeks of treatment.

Throughout the study, doctors will check how well the treatment works by examining the size and severity of the vitiligo patches. They will also ask participants questions about how vitiligo affects their daily life and overall well-being. The study will monitor any unwanted effects that might occur during treatment. Some participants may have small skin samples taken at the beginning of the study and during treatment to help researchers understand how the cream works on the skin.

]]> A Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is https://clinicaltrials.eu/trial/a-study-testing-zasocitinib-compared-to-placebo-in-adults-with-nonsegmental-vitiligo-to-see-how-well-it-works-and-how-safe-it-is/ Wed, 29 Apr 2026 15:08:13 +0000 https://clinicaltrials.eu/trial/a-study-testing-zasocitinib-compared-to-placebo-in-adults-with-nonsegmental-vitiligo-to-see-how-well-it-works-and-how-safe-it-is/ This study involves people with nonsegmental vitiligo, a condition where patches of skin lose their color because the cells that produce pigment are damaged or stop working. The treatment being tested is called zasocitinib, also known by its code name TAK-279, which is taken by mouth as a capsule. Some people in the study will receive zasocitinib while others will receive a placebo. The purpose of this study is to find out how well zasocitinib works compared to placebo in treating nonsegmental vitiligo in adults after 24 weeks of treatment.

During the study, participants will take either zasocitinib capsules or placebo capsules for up to 52 weeks. The researchers will measure how much the skin patches improve by looking at changes in the affected areas of skin on the face and the whole body. They will check whether the patches become smaller or regain their color over time. The study will compare different doses of zasocitinib to find out which dose works best and is safe for people with this condition.

The study will track several measures of improvement, including how many people see their facial skin patches improve by at least 75 percent or 50 percent from when they started the study. The researchers will also look at how much the skin patches on the face and the entire body change in size throughout the treatment period. This information will help doctors understand whether zasocitinib could be a helpful treatment option for people living with nonsegmental vitiligo.

]]> A study testing pioglitazone for adults with non-segmental vitiligo to see if it works and is safe when used with light therapy https://clinicaltrials.eu/trial/a-study-testing-pioglitazone-for-adults-with-non-segmental-vitiligo-to-see-if-it-works-and-is-safe-when-used-with-light-therapy/ Wed, 29 Apr 2026 15:07:57 +0000 https://clinicaltrials.eu/trial/a-study-testing-pioglitazone-for-adults-with-non-segmental-vitiligo-to-see-if-it-works-and-is-safe-when-used-with-light-therapy/ This study is looking at a condition called vitiligo, which is a skin disorder where patches of skin lose their color and become white. The study focuses specifically on non-segmental vitiligo, which is a type where the white patches appear on both sides of the body in a somewhat symmetrical pattern. The treatment being tested is a medication called pioglitazone, which is a type of medicine that affects how the body processes certain substances. This medication will be given as tablets and will be used together with light therapy treatment, which is a common way of treating vitiligo where the skin is exposed to specific types of light.

The purpose of this study is to find out if pioglitazone works well for treating non-segmental vitiligo, and also to check if it is safe and well-tolerated by people who take it. The study will particularly look at whether the medication can help improve the appearance of white patches on the face. People in this study will need to have tried at least one standard treatment for vitiligo before, such as creams containing corticosteroids or other specific medications, and these previous treatments will not have worked well enough for them.

During the study, participants will take pioglitazone tablets by mouth along with their light therapy treatment for a period of 16 weeks. The highest daily amount of the medication will be 15 milligrams. Throughout the study, doctors will measure how much the white patches on the face improve, particularly checking if they get at least 50 percent better compared to how they looked at the start. Women who could become pregnant will need to use reliable birth control methods during the study and for 30 days after taking the last dose of the medication. The study will check regularly to make sure the treatment is working and that participants are not having any problems with the medication.

]]> Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo https://clinicaltrials.eu/trial/study-of-ruxolitinib-cream-for-children-aged-6-to-12-years-with-non-segmental-vitiligo/ Wed, 29 Apr 2026 15:07:24 +0000 https://clinicaltrials.eu/trial/study-of-ruxolitinib-cream-for-children-aged-6-to-12-years-with-non-segmental-vitiligo/ This study focuses on children aged 6 to 12 years with nonsegmental vitiligo, a condition where patches of skin lose their color. The study will test a medication called ruxolitinib cream (also known as Opzelura) compared to a placebo cream. Vitiligo occurs when the body’s immune system attacks and destroys the cells that produce skin color, leading to white patches on the skin.

The purpose of this research is to evaluate how well ruxolitinib cream works in treating children with nonsegmental vitiligo. During the study, participants will apply either ruxolitinib cream or placebo cream to their skin. The treatment will continue for up to 52 weeks, which is approximately one year. The maximum daily amount of cream that can be used is 8.5 grams.

The study will measure how well the treatment works by looking at improvements in the affected skin areas, particularly on the face. The cream is designed for cutaneous use, which means it is applied directly to the skin. Throughout the study, doctors will monitor the participants’ health and any changes in their vitiligo patches to ensure the treatment is safe and effective.

]]> Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials https://clinicaltrials.eu/trial/long-term-safety-study-of-oral-povorcitinib-in-patients-with-hidradenitis-suppurativa-prurigo-nodularis-or-vitiligo-who-previously-participated-in-clinical-trials/ Wed, 29 Apr 2026 15:07:07 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-oral-povorcitinib-in-patients-with-hidradenitis-suppurativa-prurigo-nodularis-or-vitiligo-who-previously-participated-in-clinical-trials/ This study focuses on three skin conditions: Hidradenitis Suppurativa (a painful condition causing lumps under the skin), Prurigo Nodularis (a condition causing intensely itchy bumps on the skin), and Vitiligo (a condition where patches of skin lose their color). The study uses Povorcitinib (also known as INCB054707), which is given as tablets that are taken by mouth.

The purpose of this research is to evaluate the long-term safety of Povorcitinib in people who have previously participated in other studies of this medication. The study will continue for up to 36 months, during which participants will continue taking the medication and have their condition monitored.

This is a follow-up study specifically designed for individuals who have already completed treatment with Povorcitinib in previous research studies and have shown improvement in their condition. Throughout the study, doctors will monitor how well the medication continues to work and check for any side effects that might occur with long-term use.

]]> Study of Ritlecitinib Combined with Narrow Band UVB Light Therapy Compared to Ritlecitinib Alone in Adults with Vitiligo https://clinicaltrials.eu/trial/study-of-ritlecitinib-combined-with-narrow-band-uvb-light-therapy-compared-to-ritlecitinib-alone-in-adults-with-vitiligo/ Wed, 29 Apr 2026 15:06:54 +0000 https://clinicaltrials.eu/trial/study-of-ritlecitinib-combined-with-narrow-band-uvb-light-therapy-compared-to-ritlecitinib-alone-in-adults-with-vitiligo/ This study focuses on treating patients with vitiligo, a condition where patches of skin lose their color. The research evaluates a new medication called ritlecitinib (Litfulo), given as oral capsules, both alone and in combination with narrowband ultraviolet B light therapy (nbUVB). The purpose is to determine if combining these two treatments works better than using the medication by itself.

The treatment involves taking ritlecitinib capsules daily for 72 weeks, with some patients also receiving light therapy sessions. The maximum daily dose of the medication is 100 milligrams. During the study, doctors will measure changes in the skin’s appearance, particularly focusing on improvements in facial and total body areas affected by vitiligo.

Throughout the study, healthcare providers will monitor how well the treatment works by examining changes in the skin’s pigmentation. They will assess both the face and other body areas affected by vitiligo, and track any changes in the condition over time. The study will also evaluate how the treatment affects patients’ quality of life and their satisfaction with the results.

]]> Study on Methotrexate and Phototherapy for Adults with Progressive Vitiligo https://clinicaltrials.eu/trial/study-on-methotrexate-and-phototherapy-for-adults-with-progressive-vitiligo/ Wed, 29 Apr 2026 15:01:38 +0000 https://clinicaltrials.eu/trial/study-on-methotrexate-and-phototherapy-for-adults-with-progressive-vitiligo/ This clinical trial is focused on studying the effectiveness and safety of a treatment for vitiligo, a condition that causes patches of skin to lose their color. The study involves a combination of two treatments: methotrexate, a medication often used to treat certain autoimmune diseases, and a type of light therapy called UVB TL01 phototherapy. The purpose of the study is to evaluate how well this combination works in helping the skin regain its color in adults with progressive vitiligo, which means the condition is getting worse or spreading.

Participants in the study will receive either the combination of methotrexate and UVB TL01 phototherapy or a placebo. The study will last for about eight months, during which the participants will be monitored to see how much of their skin regains color. The study will also assess the safety of the treatment by checking for any side effects. The main goal is to see the percentage of skin that repigments, or regains color, in those receiving the combination treatment.

Throughout the study, various assessments will be conducted to measure changes in skin color and quality of life. These assessments will include the VASI score, which measures the extent of skin repigmentation, and the DLQI score, which evaluates the impact of skin conditions on daily life. Blood and skin samples will also be taken to check for any changes in inflammation. The study aims to provide valuable information on whether this combination treatment can be an effective option for people with vitiligo.

]]> Study on Anifrolumab and Phototherapy for Adults with Progressive Vitiligo https://clinicaltrials.eu/trial/study-on-anifrolumab-and-phototherapy-for-adults-with-progressive-vitiligo/ Wed, 29 Apr 2026 14:59:19 +0000 https://clinicaltrials.eu/trial/study-on-anifrolumab-and-phototherapy-for-adults-with-progressive-vitiligo/ This clinical trial is focused on studying the effects of a treatment for vitiligo, a condition that causes patches of skin to lose their color. The study involves adults with progressive, non-segmental vitiligo, which means the condition affects both sides of the body symmetrically. The treatment being tested is a combination of a medication called anifrolumab and a type of light therapy known as phototherapy. Anifrolumab, also known by its code name MEDI-546, is given through an intravenous infusion every four weeks. Phototherapy involves exposing the skin to ultraviolet B (UVB) light twice a week.

The purpose of the study is to evaluate how effective this combination treatment is in helping the skin regain its color over a period of 36 weeks. Participants will be randomly assigned to receive either the combination of anifrolumab and phototherapy or phototherapy alone. The study will monitor changes in skin pigmentation using a scoring system called the Vitiligo Area Scoring Index (VASI). This will help researchers understand how well the treatment works in repigmenting the skin.

Throughout the study, the safety and tolerability of the treatment will be assessed through clinical and biological exams. Participants will have regular check-ups to monitor their progress and any potential side effects. The study aims to provide valuable insights into the potential benefits of combining anifrolumab with phototherapy for individuals with vitiligo.

]]> Study of Ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo https://clinicaltrials.eu/trial/study-on-the-effects-of-ritlecitinib-in-adults-with-nonsegmental-vitiligo/ Wed, 29 Apr 2026 14:46:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ritlecitinib-in-adults-with-nonsegmental-vitiligo/ This clinical trial focuses on studying the effectiveness and safety of ritlecitinib in adults with nonsegmental vitiligo, a condition where patches of skin lose their color due to the destruction of pigment-producing cells. The study will test two different doses of ritlecitinib (50 mg and 100 mg) taken as oral capsules, comparing them with placebo to determine how well they work in treating vitiligo.

The study will involve taking either ritlecitinib or placebo daily for 52 weeks, followed by another 52-week extension period where dose adjustments may be made. During the study, participants may also receive dexamethasone, which is a type of steroid medication. The main goal is to see if ritlecitinib can improve the appearance of vitiligo patches, particularly on the face and other areas of the body.

Throughout the study, doctors will monitor how well the treatment works by measuring the improvement in vitiligo-affected areas and checking for any side effects. They will pay special attention to changes in the face area and overall body surface affected by vitiligo. The study will also look at how the treatment affects participants’ quality of life and emotional well-being.

]]> Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment https://clinicaltrials.eu/trial/study-on-the-effects-of-upadacitinib-in-adults-and-adolescents-with-non-segmental-vitiligo-eligible-for-systemic-treatment/ Wed, 29 Apr 2026 14:30:42 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-upadacitinib-in-adults-and-adolescents-with-non-segmental-vitiligo-eligible-for-systemic-treatment/ This clinical trial is focused on studying the effects of a medication called Upadacitinib in treating a skin condition known as non-segmental vitiligo. Non-segmental vitiligo is a condition where patches of skin lose their color. The study will involve adult and adolescent participants who are eligible for systemic therapy, which means they can receive treatment that affects the entire body, not just the skin.

The purpose of the study is to evaluate how effective, safe, and tolerable Upadacitinib is for treating non-segmental vitiligo. Participants will be randomly assigned to receive either the medication or a placebo, which is a substance with no active ingredients. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased.

Throughout the study, participants will take the medication in the form of modified-release tablets, which are designed to release the drug slowly over time. The study will last for a period of time, during which participants will be monitored for any changes in their condition and any side effects they may experience. The goal is to determine if Upadacitinib can significantly improve the skin condition of those with non-segmental vitiligo.

]]> Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-povorcitinib-for-adults-with-nonsegmental-vitiligo/ Wed, 29 Apr 2026 14:30:41 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-povorcitinib-for-adults-with-nonsegmental-vitiligo/ This clinical trial is focused on studying the effects of a medication called Povorcitinib on a skin condition known as vitiligo. Vitiligo is a condition where patches of skin lose their color, and this study specifically looks at a type called nonsegmental vitiligo, which is the most common form. The purpose of the study is to compare the effectiveness of Povorcitinib to a placebo in treating this condition over a period of 52 weeks.

Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The medication is taken orally in the form of a tablet.

The study will last for about a year, during which participants will be monitored to see if there is an improvement in their vitiligo. The main goal is to see if participants achieve a significant improvement in their skin condition by the end of the study. Participants will have regular check-ups and assessments to track their progress and ensure their safety throughout the trial.

]]> Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-povorcitinib-for-adults-with-nonsegmental-vitiligo-2/ Wed, 29 Apr 2026 14:30:32 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-povorcitinib-for-adults-with-nonsegmental-vitiligo-2/ This clinical trial is focused on studying the effects of a medication called Povorcitinib in individuals with a skin condition known as vitiligo. Vitiligo is a condition where patches of skin lose their color, leading to lighter areas on the body. The study will specifically look at a type of vitiligo called nonsegmental vitiligo, which is the most common form and can appear on both sides of the body. Participants in the study will receive either Povorcitinib or a placebo, which is a substance with no active medication, to compare the effectiveness of the treatment.

The purpose of the study is to evaluate how well Povorcitinib works in improving the skin condition over a period of 52 weeks. Participants will take the medication in the form of a tablet by mouth. Throughout the study, researchers will monitor changes in the skin, particularly looking for improvements in the color of the skin on the face and body. The study aims to see if participants experience at least a 75% improvement in their skin condition by the end of the study period.

Participants will be involved in the study for about a year, during which they will have regular check-ups to assess their progress. The study will help determine if Povorcitinib is a safe and effective treatment option for people with nonsegmental vitiligo. This research could potentially lead to new treatment options for those affected by this skin condition.

]]> Study on Afamelanotide and NB-UVB Light for Vitiligo Treatment in Patients with Vitiligo https://clinicaltrials.eu/trial/study-on-afamelanotide-and-nb-uvb-light-for-vitiligo-treatment-in-patients-with-vitiligo/ Wed, 29 Apr 2026 14:30:05 +0000 https://clinicaltrials.eu/trial/study-on-afamelanotide-and-nb-uvb-light-for-vitiligo-treatment-in-patients-with-vitiligo/ This clinical trial is focused on studying vitiligo, a condition where the skin loses its pigment, resulting in white patches. The study will explore the effectiveness and safety of a treatment involving a medication called SCENESSE (which contains the active substance afamelanotide) combined with a type of light therapy known as Narrow-Band Ultraviolet B (NB-UVB) light. The trial will compare this combination treatment to the use of NB-UVB light therapy alone.

The purpose of the study is to evaluate how well the combination of SCENESSE and NB-UVB light therapy works in helping the skin regain its color compared to using NB-UVB light therapy by itself. Participants in the study will receive either the combination treatment or just the NB-UVB light therapy. The study will monitor the progress of repigmentation, which is the return of color to the skin, and will also look at how quickly this repigmentation begins, especially on the face.

The trial is designed to provide insights into whether adding SCENESSE to the NB-UVB light therapy can improve outcomes for people with vitiligo. The study will take place over a period of time, and participants will be observed to see how their skin responds to the treatments. The findings from this study could help in understanding better ways to manage and treat vitiligo in the future.

]]> Study on the Safety and Effectiveness of Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ritlecitinib-in-adults-and-adolescents-with-nonsegmental-vitiligo/ Wed, 29 Apr 2026 14:29:51 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ritlecitinib-in-adults-and-adolescents-with-nonsegmental-vitiligo/ This clinical trial is focused on studying the effects of a medication called Ritlecitinib on a skin condition known as nonsegmental vitiligo. Nonsegmental vitiligo is a condition where patches of skin lose their color, leading to white spots on various parts of the body. The study will use two different doses of Ritlecitinib, 50 mg and 100 mg, taken as capsules. The purpose of the study is to evaluate the long-term safety and how well people tolerate these doses of Ritlecitinib.

Participants in the study will be adults and adolescents who have nonsegmental vitiligo. The study will involve a period where participants will take the medication, and their response to the treatment will be monitored. Some participants may receive a placebo, which is a capsule that looks like the medication but does not contain the active ingredient. The study will help researchers understand how effective Ritlecitinib is in treating nonsegmental vitiligo and whether it is safe for long-term use.

Throughout the study, participants will be regularly checked for any side effects or changes in their condition. The study aims to provide valuable information on the potential benefits and risks of using Ritlecitinib for treating nonsegmental vitiligo, contributing to better treatment options for those affected by this condition.

]]> Study on the Effects of Ruxolitinib Cream for Patients with Genital Vitiligo https://clinicaltrials.eu/trial/study-on-the-effects-of-ruxolitinib-cream-for-patients-with-genital-vitiligo/ Wed, 29 Apr 2026 14:26:56 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ruxolitinib-cream-for-patients-with-genital-vitiligo/ This clinical trial is focused on studying vitiligo, a condition that causes patches of skin to lose their color. Specifically, the study is looking at nonsegmental vitiligo that affects the genital area. The treatment being tested is a cream containing ruxolitinib, which is applied directly to the skin. The purpose of the study is to see if this cream can help restore skin color in the affected areas.

Participants in the study will use the ruxolitinib cream for a period of time, and researchers will monitor any changes in skin color. The study will also track any side effects or changes in health that may occur during the treatment. The goal is to determine if the cream is safe and effective for treating vitiligo in the genital region.

Throughout the study, participants will have regular check-ups to assess the progress of the treatment. The study aims to find out if the cream can make the vitiligo patches less noticeable or even restore the skin to its normal color. This research could provide valuable insights into new treatment options for people with vitiligo.

]]> Study on Pioglitazone for Adults with Non-Segmental Vitiligo https://clinicaltrials.eu/trial/study-on-pioglitazone-for-adults-with-non-segmental-vitiligo/ Wed, 29 Apr 2026 14:23:18 +0000 https://clinicaltrials.eu/trial/study-on-pioglitazone-for-adults-with-non-segmental-vitiligo/ This clinical trial is focused on studying the effects of a medication called Pioglitazone on a skin condition known as non-segmental vitiligo. Non-segmental vitiligo is a condition where patches of skin lose their color, leading to white spots on various parts of the body. The study aims to understand how effective and safe Pioglitazone is when used alongside a type of light therapy called NB-UVB, compared to using the light therapy alone.

Participants in the study will be adults who have active non-segmental vitiligo. The study will last for a period of 32 weeks. During this time, participants will receive either the combination of Pioglitazone and NB-UVB or just NB-UVB treatment. The goal is to see if there is at least a 50% improvement in the skin condition by the end of the study. Participants will also be asked to assess their own quality of life related to their skin condition throughout the study.

The study will help determine if adding Pioglitazone to the existing light therapy can provide better results for people with non-segmental vitiligo. This information could be valuable for developing more effective treatment options for this condition in the future.

]]>